Agilis Biotherapeutics snags $8 mln

According to a news announcement on its site, Agilis Biotherapeutics has closed $8 million in funding. The investors were not named. The financing  will be used to develop a treatment for Friedreich’s ataxia in partnership with Intrexon Corp. Based in New York, Agilis is a biotech company focused on rare genetic diseases. To read further details about the funding, visit here.

Related Posts

Leave a Reply

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups